Von Willebrand disease and its management in oral and maxillofacial surgery

Wilde, J. T.; Cook, Rosalind

doi:10.1016/s0266-4356(98)90178-4

Cited by 19 publications

(36 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to other previous reports which suggested an accurate evaluation of plasma FVIII/vWF activities before and after systemic therapies with DDAVP and vWFc [9], our study shows that monitoring of the FVIII/vWF before and after oral surgery is not strictly necessary. Of course, the previous and appropriate characterization of vWD patients and the close collaboration between the haematologists and the oral surgeons might have made unnecessary the need of further monitoring during oral surgery.…”

Section: Discussioncontrasting

confidence: 70%

Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases

et al. 2000

View full text Add to dashboard Cite

Bleeding after dental extractions is very frequent in patients with von Willebrand disease (vWD) and in the past often necessitated transfusions with factor VIII/von Willebrand factor concentrates (vWFc). To evaluate the benefits of a standard local therapy on bleeding complications during oral surgery, 63 consecutive patients with vWD were analysed retrospectively. All types of vWD were included: type 1 (n=31), type 2 (n=22) and type 3 (n=10). All the patients had dental extractions or periodontal surgery at the same hospital by the same oral surgeons. All cases had been given tranexamic acid (TA) before and for 7 days after surgery. As additional local therapy fibrin glue (FG) was used during surgery in several patients. Additional systemic therapies were: desmopressin (DDAVP, 0.3 microg kg-1) and fVIII/vWF concentrates (vWFc, 40 U kg-1) given as a single dose before surgery. The 29 subjects (46%) treated locally did not bleed. Among the remaining cases, 24 (38%) were given DDAVP as additional systemic therapy and 6 (9.5%) received vWFc. There was bleeding after surgery in only two cases who had been given local FG (type 2 B) or systemic vWFc (type 3), but bleeding was stopped with an additional local application of FG. Our data suggest that a standard local therapy with TA and FG with DDAVP can prevent bleeding complications during oral surgery in the majority of patients (84%) with vWD and reduce the need for concentrates, with all their possible complications and high costs.

show abstract

Section: Discussioncontrasting

confidence: 70%

Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Bleeding after dental extractions may be a presenting feature of this condition. 15,16 Clinical manifestations include mucocutaneous haemorrhage and gingival bleeding, features that are secondary to platelet dysfunction. There are three subtypes of vWD (Table 2) and patients in each subtype may be categorised into mild, moderate and severe at the time of diagnosis.…”

Section: Von Willebrand Disease (Vwd)mentioning

confidence: 99%

Guidance on the dental management of patients with haemophilia and congenital bleeding disorders

Anderson¹,

Brewer²,

Creagh³

et al. 2013

Br Dent J

134

View full text Add to dashboard Cite

Recommendations for dental preventive strategies and treatment planning were originally developed through consensus meetings by the Scottish Oral Health Group for Medically Compromised Patients and published in 2003 as a Guideline. The United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) Dental Working Party has updated these recommendations following the AGREE II approach (www.agreetrust.org), involving a literature search, a review of national and international guidelines and after seeking the opinions of haemophilia treaters in the United Kingdom by an online survey. Where possible, evidence from the literature is graded according to the 'GRADE' system (www.bcshguidelines.com/bsch_process/evidence_levels_and_grades_of_recommendations/43_grade.html); however, overall there is a lack of robust data and most studies have methodological limitations. The objective of this guidance, which is largely consensus-based, is to assist dental practitioners in primary and secondary care to provide routine dental care for patients of all ages with congenital bleeding diatheses in order to improve overall access to dental care. The guidance may not be appropriate in all cases and individual patient circumstances may dictate an alternative approach. Date for guideline review: May 2016.

show abstract

“…Während die Thrombozytenaggregationshemmer im Wesentlichen zur Herzinfarkt-und Schlaganfallprophylaxe eingesetzt werden, kommen Vitamin-K-Antagonisten bei Z. n. Herzklappenersatz, Herzrythmusstörungen mit der Gefahr kardiogener Hirn embolien und zur Langzeitprophylaxe von Lungenembolien zum Einsatz. Die relativ seltenen angeborenen Störungen der Blutgerinnung [26]…”

Section: Kardiovaskuläre Erkrankungenunclassified